A new drug to prevent the early stages of Alzheimer's disease could enter clinical trials in a few years' time according to scientists.
Alzheimer's is the most common type of dementia, which currently affects 820,000 people in the UK, with numbers expected to more than double by 2050. One in three people over 65 will die with dementia.
The disease begins with the formation of senile plaques in the brain, damaging nerve cells and leading to memory loss and confusion.
Professor David Allsop and Dr Mark Taylor at Lancaster University have successfully created a new drug which can reduce the number of senile plaques by a third. Prof Allsop talks about the new drug while we see Dr Taylor in the lab.